Kestra Medical Technologies, LTD. cash flow statement

In fiscal 2026, Kestra Medical Technologies, LTD.'s operations generated −$81.7m of cash; it spent $34.9m on capital projects, leaving free cash flow of −$117m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Kestra Medical Technologies, LTD.: cash flow statement, annual
Fiscal year	2024Apr 2024	2025Apr 2025	2026Apr 2026	LTMJul 2026
Cash from operations	−72	−78	−82	−88
Depreciation and amortisation	12	8	9	9
Stock-based pay	1	24	34	39
Capital spending	12	23	35	35
Free cash flow	−84	−101	−117	−123
Free cash flow after stock pay	−86	−125	−150	−161
Shares issued	—	216	149	—

US$ millions unless shown otherwise. Fiscal quarters.

Kestra Medical Technologies, LTD.: cash flow statement, quarterly
Quarter	2025 Q2Oct 2024	2025 Q3Jan 2025	2025 Q4Apr 2025	2026 Q1Jul 2025	2026 Q2Oct 2025	2026 Q3Jan 2026	2026 Q4Apr 2026	2027 Q1Jul 2026
Cash from operations	−18	−18	−24	−26	−18	−18	−19	−32
Depreciation and amortisation	2	2	2	2	2	2	2	3
Stock-based pay	1	0	22	5	9	10	10	10
Capital spending	4	4	7	8	7	10	10	8
Free cash flow	−23	−22	−31	−34	−26	−28	−28	−41
Free cash flow after stock pay	−24	−23	−54	−39	−34	−38	−39	−50
Shares issued	—	—	—	—	—	—	0	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: KMTS vs XTNT KMTS vs SMTI CBLL vs KMTS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Kestra Medical Technologies, LTD.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kestra Medical Technologies, LTD.